The Global Liver
Fibrosis Treatment Market, segmented by Treatment Type (Peroxisome
Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors,
Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, Hepatitis
C, and Nonalcoholic Steatohepatitis), by End User (Hospitals, Specialty
Clinics, and Others), and by Region (North America, Latin America, Europe, Asia
Pacific, the Middle East, and Africa) is projected to exhibit a CAGR of 10.8%
over the forecast period (2018 - 2026).
Increasing number of clinical
trials by key players focused on development of an efficient treatment option
for liver fibrosis is expected to drive the growth of the liver fibrosis
treatment market in near future. In October 2010, FibroGen, Inc. initiated
phase II clinical study of FG-3019: a human monoclonal antibody against the
Connective Tissue Growth Factor (CTGF) to compare the efficacy in reversing the
effects of liver fibrosis caused by chronic infection with hepatitis B virus
(HBV). In February 2018, Intercept Pharmaceuticals, Inc. initiated phase III
trial of REVERSE trial (Randomized Phase 3 Study Evaluating the Efficacy and
Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis Due to
Nonalcoholic Steatohepatitis). This randomized phase III study will evaluate
the efficacy and safety of obeticholic acid in NASH patients with a
biopsy-confirmed diagnosis of cirrhosis.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2320
Browse 24 Market Data Tables and
28 Figures spread through 168 Pages and in-depth TOC on ‘Liver Fibrosis
Treatment Market, by Treatment Type (Peroxisome Proliferator-activated
Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others),
by Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic
Steatohepatitis), by End User (Hospitals, Specialty Clinics, and Others), and
by Region (North America, Latin America, Europe, Asia Pacific, the Middle East,
and Africa) - Global Forecast to 2026’
Furthermore, growing research collaboration
among the key players to develop novel treatment regime combined with
regulatory approval of underline drugs for treatment of liver fibrosis is
expected to drive the market growth in near future. For instance, in April
2017, Bristol-Myers Squibb Company and Nordic Bioscience signed a collaboration
agreement for development of biomarker technology to potentially diagnose and
monitor fibrosis disease including Non-alcoholic steatohepatitis (NASH). This
collaboration will help patients to efficiently diagnose and monitor fibrosis
disease. In February 2018, the U.S. Food
and Drug Administration (FDA) approved Vertex Pharmaceuticals’ SYMDEKO
(tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF)
in people age 12 and older with certain mutations.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/liver-fibrosis-treatment-market-2320
Key Takeaways of the Liver
Fibrosis Treatment Market:
The global liver fibrosis
treatment market is expected to grow at 10.8% CAGR over the forecast period,
owing to increasing prevalence of risk factors affecting liver fibrosis,
worldwide.
Among treatment type, hepatotropic
drug accounted for significant market share in liver fibrosis treatment market,
as it enables safe and efficient treatment for reducing fibrosis in patients.
Among end users, hospitals
segment is expected to account for major market share during the forecast
period, as hospital offer primary treatment option for patient suffering with
liver fibrosis.
Some of the major players
operating in the global liver fibrosis treatment market include Gilead
Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and
Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc.,
FibroGen, Inc., and Pharmaxis Limited.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2320
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment